Robert-Jan Schipper
Overview
Explore the profile of Robert-Jan Schipper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Veer E, Coolen A, Bluekens A, Generaal M, Schipper R, Setz-Pels W, et al.
Breast
. 2025 Jan;
80:103886.
PMID: 39847912
Background: The effectiveness of the Dutch breast cancer screening programme depends on the quality of the full trajectory, from the first screening to the final treatment of a screen-detected breast...
2.
Walstra C, Schipper R, Voogd A, van der Sangen M, van Duin R, van Riet Y, et al.
Eur J Surg Oncol
. 2025 Jan;
51(5):109564.
PMID: 39826447
Background: In line with the trend towards minimally invasive, patient-tailored treatment, a selected group of patients with an in-breast tumour recurrence (IBTR) is treated by repeat breast-conserving treatment (BCT). To...
3.
de Bruijn A, Schipper R, Voogd A, Pullens M, Bloemen J, de Munck L, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766087
: Data are lacking on the optimal neoadjuvant systemic treatment (NST) for women with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-positive (HER2+) breast cancer if they are unfit...
4.
van der Voort A, van der Hoogt K, Wessels R, Schipper R, Wesseling J, Sonke G, et al.
Eur Radiol
. 2024 Aug;
PMID: 39136708
No abstract available.
5.
OLeary R, Duijm L, Boersma L, van der Sangen M, de Munck L, Wesseling J, et al.
Br J Cancer
. 2024 Jul;
131(5):852-859.
PMID: 38982194
Background: The first aim of this study was to examine trends in the risk of ipsilateral invasive breast cancer (iIBC) after breast-conserving surgery (BCS) of ductal carcinoma in situ (DCIS)....
6.
van der Voort A, van der Hoogt K, Wessels R, Schipper R, Wesseling J, Sonke G, et al.
Eur Radiol
. 2024 Jul;
34(12):7994-8004.
PMID: 38967659
Objectives: The aim of this study is to investigate the added value of diffusion-weighted imaging (DWI) to dynamic-contrast enhanced (DCE)-MRI to identify a pathological complete response (pCR) in patients with...
7.
Schipper R, de Bruijn A, van der Sangen M, Bloemen J, van den Hoven I, Schepers E, et al.
Eur J Surg Oncol
. 2024 Jun;
50(9):108472.
PMID: 38870876
Background: The aim of the present study was to report the 5-year axillary recurrence-free interval (aRFI) in clinically node-positive breast cancer patients treated according to a de-escalating axillary treatment protocol...
8.
de Jonge C, Schipper R, Walstra C, van Riet Y, Verrijssen A, Voogd A, et al.
Int J Cancer
. 2024 May;
155(7):1237-1247.
PMID: 38752603
Recent studies have reported a higher than expected risk of ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS) and a single dose of electron beam intra-operative radiotherapy (IORT)....
9.
de Wild S, van Roozendaal L, de Wilt J, van Dalen T, van der Hage J, van Duijnhoven F, et al.
Br J Surg
. 2024 Apr;
111(4).
PMID: 38597154
Background: Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in...
10.
Ten Velde D, Duijm L, van der Sangen M, Schipper R, Tjan-Heijnen V, Vreuls W, et al.
Br J Cancer
. 2024 Mar;
130(9):1561-1570.
PMID: 38467826
Background: No studies are available in which changes over time in characteristics and prognosis of patients with interval breast cancers (ICs) and screen-detected breast cancers (SDCs) have been compared. The...